Post Reply
3881-3900 of 10899
it break the resistance!!!! HIGH is 0.84!!! closing at 0.835! Bullish Signal detected!!!
a Bullish uptrend might follow???
On Wednesday, Biosensor gap up from the support at $0.795 and closed at $0.81 with HIGH volume of 6.56 million shares traded.
A doji star occurred (where a doji gaps above or below the previous candle). This often signals a reversal with confirmation occurring on the next bar.
Both RSI & MACD are turning bullish as MACD about to perform a “golden cross”
Important Resistance of Biosensor: $0.825
Immediate Support of Biosensor: $0.795
Currently prices are supported by the technical / 50/100/200 days MA at $0.795
As seen from the charts, Biosensor has been forming an bullish pattern “ascending triangle” since Mar10.
Any breakout above $0.825 will be considered a bullish signal for Biosensors.
SEE ANALYSIS FOR COSCO
We would advise investors to keep a look out if the major resistance at $0.825 can be broken at high volume for buying opportunities.
sorry about the d earlier post repeating 3 times ...must have been too happy hehe. From DJ news
DJ MARKET TALK: Biosensors May Gain; Gets
Nod To Sell In Taiwan (2010/08/18 08:56AM)
0056 GMT [Dow Jones] Biosensors (B20.SG) may gain on prospect of higher
revenue as heart-stent maker receives regulatory approval to sell its flagship
BioMatrix stent in Taiwan. Greenlight follows approvals earlier this year to
sell BioMatrix in France, late last year in South Korea. Stent sales +53% on
year to US$17.6 million in June quarter. Potentially higher sales following
Taiwan approval may help mitigate impact of higher R&D expenses for current
FY ending March 2011 flagged recently by company as it continues to invest in
new products. Bottomline, however, expected to improve due to cost savings from
recent closure of U.S. operations. Shares end flat at S$0.80 yesterday. Pre-open
quotes bids of up to S$0.84, offers mostly at S$0.845. (frankie.ho@dowjones.com)
Well, at least the new president Jump likes to talk to the press. Perhaps this will keep the company's name front and center.
Maybe someone will concentrate on the Asia focused Mutual funds! I think there are over 200 based in the US that invest in companies located here, China, Korea, Malaysia, India, Indonesia, Japan etc. Plus all the mutual funds that specialize in eastern europe.
=DJ INTERVIEW: Biosensors CEO: Looking To Develop Non-Coronary Stent Business (2010/08/03 16:27PM)
By Sam Holmes
Of DOW JONES NEWSWIRES
SINGAPORE (Dow Jones)--Singapore biomedical manufacturer Biosensors International Group Ltd. (B20.SG) Chief Executive Jeffrey Jump said the company is now looking to develop products using its stent technology for applications outside the heart.
The company last month acquired some of the assets of California-based CardioMind Inc., which makes stents that are 70% smaller than those commonly available, a move that Jump hopes will allow Biosensors to develop drug-eluting stent products--man-made tubes designed to support arteries--for use in smaller vessels throughout the body such as those in the brain and peripheral arteries.
"Right now we''re only focused on coronaries but this will work on peripheral, for example below the knee or foot," Jump told Dow Jones Newswires in an interview.
"(Neurology is) where cardiology was 15 years ago so it allows us to be at the forefront of this new market technology."
Biosensors'' results for the first quarter ended June 30 announced earlier last week showed a net profit of US$3.2 million, down 23% from a year earlier, reflecting the US$6.0 million charge taken for the closure of its U.S. operations.
The weaker euro this year has also affected its revenue, much of which is derived from European markets and exchanged into U.S. dollars.
However, Jump said that despite the currency volatility, the company maintains its revenue guidance of US$135 million to US$145 million for the 2011 financial year. Biosensors reported revenue of US$33.0 million for its fiscal first quarter.
Jump also said "there are discussions that go on all the time" with other companies in relation to merger opportunities but that Biosensors isn''t looking to make itself an acquisition target for larger drug-eluting stent producers.
The drug-eluting stent business is dominated by four large U.S. biomedical groups: Abbott Laboratories, Johnson & Johnson (JNJ), Boston Scientific Corp. (BSX), Abbott Laboratories (ABT) and Medtronic Inc. (MDT).
"If somebody wanted to step in and offer a premium, that can always happen but that''s not how we''re running the company," he said. "I think we probably are continuing to be annoying to at least three of the big four."
-By Sam Holmes, Dow Jones Newswires; +65-6415-4157; samuel.holmes@dowjones.com
On Friday, Biosensor continues to trend inside the channel region and closed at $0.815 with moderate volume of 5.43 million shares traded.
A short black candle sticks with no upper/lower shadow indicates low interest from the investors.
Both RSI & MACD are bearish as MACD perform a “cross down” on Friday.
Important Resistance of Biosensor: $0.83
Immediate Support of Biosensor: $0.795
Currently prices are supported by the technical /20 days MA at $0.795.
It is clear that Biosensor has problem breaking the major resistance at $0.83 despite 3 solid attempts at April/May/July 2010 respectively.
SEE ANALYSIS FOR OLAM
Although Biosensor seems to be forming a symmetrical triangle with “higher high” and “higher low” but we do not advise to enter till $0.83 resistance can be broken at high volume.
I think that it is a matter of time before more institutions become interested in Biosensors. (Provided everything goes according to their future projections and plans).
Why ? Biosensors only became profitable in FY 2010 end Mar. At the last Q1 2011 conference, there were several new stockbroking firm analysts present, namely DBS Vickers, Lim & Tan, Kim Eng and even UBS (who previously used to cover Biosensors but had drop coverage).
The new analysts will take time to be acquainted with Biosensors' business (They need to differentiate MACE, TLR, Late loss, etc, patent etc.)
Even if Terumo is not interested in Biosensors, - It does not matter. WHat matters is that they are at the mercy of the licensing business.
They paid US$40m upfront to negotiate reduction in royalties for a 5 yr period, and there is left only 2 1/2 yrs.
Their aggressiveness in the big clinical trials in Europe and the coming approval in Japan shows that this is a profit spinner for them and Biosensors.
They paid US$3.6m in royalties in Q1 and assuming that this is 25 % of their revenue, that means their revenue is US$14.4m. As gross margins are high (Biosensors gross margin is probably above 80 %), profit attributable to them should be OK.
If you look at total sales, based on current Q1 results, Biosensors generate US$17.6m, Terumo generate US$14.4m (estimates) and JWMS generate US$23m (of which 11.5m belongs to Biosensors, then total DES sales for Q1 is US$43.5m, annualising it, you get US$174m - an impressive figure for a new startup.
Biosensors is predicting that their own DES sales will increase 40 % this yr, and I am sure that Terumo, JWMS will also generate increase in sales. (Note we are not including future sales from Japan)
GOing forward, if things panned out - no reason not to expect more interest in Biosensors.
Above are conjectures only - may not necessary turn out to be true. Not a call to buy/sell.
I agree with Senior's points. However Terumo does not have a history of making acquisitions at reasonable prices, they are bargain hunters. I believe the most they paid for a company was under a $ billion; and that deal had a very strong "earn-out" component. Biosenors is controlled by a few major shareholders and they do not seem interested in bargain prices.
What truly puzzles me is that BIG has very few institutional investors. Why hasn't the company retained a "sell side" firm to help it raise visibility with all the mutual funds aimed at Asia? BIG is a serious contender in all these fast growth markets.
Just don't get it.
Apologies - The projected revenue from Japan for Terumo should be US$120m, assuming they have a 20 % share of the mkt. (Japan's mkt is approx US$600m).
Nomura held a post results lunch meeting with the CEO of Biosensors. Key points from the meeting :
1) The CEO believes that the China mkt will be as big as US (ie US$2 billion) by 2015. (And JWMS is the no 3 player in China right now)
2) Acquisition of Cardiomind reflects new strategy to expand product line, of which there will be more of such acquisitions.
3) Biofreedom will be their important Trump Card - It will reduce the need to have dual antiplatet drug therapy, and CEO believes that this product will have a good chance of making a difference in the US mkt.
4) Royalties from Terumo reflects Terumo's success in Europe, Asia, Latin AMerica and the mgmt is looking forward to the approval of Nobori in Japan to drive a new source of revenue.
My own thinking on Terumo - They are aggressive in conducting major clinical trials in Europe. Their license from Biosensors is for a period of 5 year (of which I believe 2 and 1/2 yrs have passed !).
I believe that when they get approval in Japan and if they get a 20 % or more mkt share, this will translate to a revenue of US$200m, coupled with revenue from Europe, then they will start worrying, as they cannot control what will happen, when the license expires.
Also, Biosensors is rapidly coming out with new products - Biomatrix flex, Biofreedom, Cardiomind - what is the impact to them ?
Some superficial conjectures. - Not a call to buy/sell.
It is regrettable that TERUMO is such a timid organization. It seems that if TERUMO acquired BIG it could quickly become a leader in the INTERVENTIONAL space in CHINA and other fast growing areas of the word, while lsimultaneously broadening their interventional line with the addition of BIG's small stent and new drug delivery technology. IT could also provide access to DEVAX's new untapped market.
Too bad they do not seem to grasp the big picture.
Event. According to its press release dated July 29 2010,
Devax Inc announced that the company has recevied CE Mark for its AXXESS Biolimus A9 Eluting Bifurcation Stent System, allowing the company to initiate sales in the EU and other CE markets (mainly Asia ex-Japan,
Licensing agreement with BIG.
Under a licensing agreement dated December 2003, Biosensors is entitled to:
i) receive royalties, including an annual minimum royalty, based on an undisclosed percentage of AXXESS revenue and
ii) provide stent-coating services to Devax at a premium above cost.
How big is the "bifurcation" market? According to In Vivo, bifurcation disease (vascular disease located at the division of one artery into two) remains one of the largest unmet clinical needs in interventional cardiology, affecting roughly 20% of patients who undergo PCI;
the potential market size is esimated to be US$1.3bn worldwide.
Based on our preliminary research, AXXESS is one of the few pioneers in this technology with a CE mark, and none of the Big Fours has been successful in commercializing a similar product so far.
More possibilities going forward? Biosensors' new CEO Jeff Jump's key strategy going forward is to broaden its product range to better leverage on its existing sales/R&D/manufacturing infrastructure, via both acquisitions and internal R&D.
Therefore we think there are more possibilities to this partnership, which could potentially involve a distributorship.
In this regard, we believe Biosensors would be able to provide speed-to-market by sharing its knowledge base on reiumbursement approval process in key markets such as
Potential royalties not in our estimates. We have not factored in the potential royalty stream and stent-coating revenue from Devax given the lack of visibility over the approval timeline previously and the undisclosed royalty formula
. While the cashflow potential is unlikely to match Terumo's licensing agreement,
we think this reaffirms
our investment thesis that there is significant value to be unlocked at Biosensors.
Reiterate BUY.
compare the 2 headlines.
YET DBS had 2Q loss of $300m
whilst BIG had net profit of us $3.24m
gbleng ( Date: 30-Jul-2010 10:11) Posted:
|
topdog22 ( Date: 29-Jul-2010 08:33) Posted:
|
Wrong thread, but just for sharing.
|
July 30, 2010, 8.18 am (Singapore time)  |
|
|
Update: DBS posts Q2 loss after surprise HK goodwill charge
DBS Group, Southeast Asia's biggest bank, said, however, that the outlook remained healthy. 'Notwithstanding the goodwill impairment, we remain structurally bullish on prospects for Hong Kong and China, which are integral to the Asia growth story,' CEO Piyush Gupta said in a statement.
SINGAPORE - DBS Group, Southeast Asia's biggest bank, posted a surprise quarterly loss after it took a S$1.02 billion (US$748.9 million) goodwill charge for its Hong Kong operations.
|
gbleng ( Date: 30-Jul-2010 10:11) Posted:
|
Just read in Nomura's report today, that Biosensor's Licensee, Devax has got the CE Mark for their drug eluting stent for bifurcation lesions.
As Devax is a small company, and if they cannot mkt or manufacture their own DES, this is where Biosensor's mkting and manufacturing structure comes in .(That is what the CEO mean by new technologies leveraging on the infrastructure of Biosensors).
However, please note that IT IS NOT the case at the moment, ie this is only conjecture on my part - Devax has not yet approach Biosensors on the above.
Biosensors will be entitiled to royalties from the sale of Devax's DES, just like Terumo's sales.
For info. Not a call to buy/sell.
Posted: 30 July 2010 0806 hrs . No mention of $1bn charge in the headline news... see what i mean about selective reporting...